Abstract
A chemo-immunotherapy program was designed on the basis of our clinical findings, which revealed that the ability to generate cell-mediated cytotoxicity was remarkably augmented after adriamycin (AM) administration in cancer patients. Twenty patients with stage IV gastric carcinoma who had undergone noncurative resections were treated with the above regimen that consisted of active immunotherapy with autologous tumor cells, in combination with 30 mg of AM, given 7 days before the immunization, followed by long-term tegafur (FT) and immunomodulators. The survival of these patients was compared to that of 3 other groups of patients, namely; 30 patients treated with another chemo-immunotherapy regimen which comprised autologous tumor cells in combination with several anticancer drugs followed by long-term FT and immunomodulators (CCI1), 17 patients treated with mitomycin C followed by long-term FT and immunomodulators (CI), and 24 patients with comparable histories (HC). The first treatment group had significantly improved survival, as compared to the HC group (p<0.01) and the survival tended also to be more favorable, when compared to the CCIl group (p<0.2) or the CI group (p<0.2). Moreover, the survival rate at 9 months was significantly higher than that of either the CCI1 group (p<0.01) or the CI group (p<0.01).
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kataoka T, Kobayashi H, Sakurai Y. Potentiation of concanavarin A-bound L1210 vaccinein vivo by chemotherapeutic agents. Cancer Res 1978; 38: 1202–1207.
Glaser M. Regulation of specific cell-mediated cytotoxic response against SV40-induced tumor associated antigens by depletion of suppressor T cells with cyclophophamide in mice. J Exp Med 1979; 149: 774–779.
Mizushima Y, Sendo F, Takeichi N, Hosokawa M, Kobayashi H. Enhancement of antitumor transplantation resistance in rats by appropriately timed administration of busulfan. Cancer Res 1981; 41: 2917–2921.
Akiyoshi T, Kawaguchi M, Miyazaki S, Koba F, Tsuji H. Sequential combination chemo-immunotherapy for various malignant tumors: Clinical and laboratory results. Jpn J Surg 1981; 11: 283–290.
Kawaguchi M, Akiyoshi T, Miyazaki S, Tsuji H. Chemo-immunotherapy against murine fibrosarcoma: Efficacy of a treatment regimen designed on the basis of the effect of anticancer drugs on immune response. Bull Inst Balneother 1982; 33: 139–146.
Akiyoshi T, Kawaguchi M, Arinaga S, Miyazaki S, Koba F, Wada T, Tsuji H. A trial of adjuvant combination chemo-immunotherapy for stage III carcinoma of stomach. J Surg Oncol 1984; 36: 86–90.
Orsini F, Pavelic Z, Mihich E. Increased primary cell-mediated immunity in culture subsequent to adriamycin or daunorubicin treatment of spleen donor mice. Cancer Res 1977; 37: 1719–1726.
Tomazic V, Ehrke MJ, Mihich E. Augmentation of the development of immune response of mice against allogeneic tumor cells after adriamycin treatment. Cancer Res 1981; 41: 3370–3376.
Ehrke MJ, Tomazic V, Ryoyama K, Cohen SA, Mihich E. Adriamycin induced immunomodulation: Dependence upon time of administration. Int J Immunopharmac 1983; 5: 43–48.
Ehrke MJ, Ryoyama K, Cohen SA. Cellular basis for adriamycin-induced augmentation of cell-mediated cytotoxicity in culture. Cancer Res 1984; 44: 2497–2504.
Arinaga S, Akiyoshi T, Tsuji H. Augmentation of the generation of cell-mediated cytotoxicity after a single dose of adriamycin in cancer patients. Cancer Res 1986; 46: 4213–4216.
Japanese Research Society for Gastric Cancer. The general rules for gastric cancer study in surgery and pathology. Jpn J Surg 1983; 11: 127–129.
Peters LC, Brandhorst JS, Hanna MG. Preparation of immunotherapeutic autologous tumor cell vacine from solid tumors. Cancer Res 1979; 39: 1353–1356.
Aoki T, Kvedar JP, Hollis VW, Bushar GS. Streptococcus pyogenes preparation OK-432: Immunoprophylactic and immunotherapeutic effects on the incidence of spontaneous leukemia in AKR mice. J Natl Cancer Inst 1976; 56: 687–690.
Tsukagoshi S, Ohashi F. Protein-bound polysaccharide, PSK, effective against mouse sarcoma-180 and rat ascites hepatoma AH-13 by oral use. Gann 1974; 65: 557–558.
Tykka H, Hjelt L, Oravisto KJ, Turunen M, Tallberg T. Disappearance of lung metastases during immunotherapy in five patients suffering from renal carcinoma. Scan J Res Dis 1974; 89 (Suppl): 123–134.
McCune CS, Schapiro DV, Henshaw EC. Specific immunotherapy of advanced renal carcinoma: Evidence for the polyclonality of metastases. Cancer 1981; 47: 1984–1987.
Takita H, Hollishead A, Hart T Jr, Bhayana J, Adler R, Rao U, Moskowitz R, Ramundo M. Adjuvant specific immunotherapy of resectable squamous cell lung carcinoma, analysis at the eighth year. Cancer Immunol Immunother 1985; 20: 231–235.
Hoover HC Jr, Surdyke MG, Dangel RB, Peters LC, Hanna MG. Prospectively randomized trial of adjuvant active-immunotherapy for human colorectal cancer. Cancer 1985; 55: 1236–1243.
Hollishead A, Stewart HM, Takita H, Dalbow M, Concannon J. Adjuvant specific active lung cancer immunotherapy trials. Tumor-associated antigens. Cancer 1987; 60: 1249–1262.
Berd D, Maguire HC, Mastrangelo MJ. Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res 1986; 46: 2572–2577.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Akiyoshi, T., Arinaga, S., Takamuku, K. et al. A trial of postoperative adjuvant combination chemo-immunotherapy for stage IV gastric carcinoma. The Japanese Journal of Surgery 18, 521–526 (1988). https://doi.org/10.1007/BF02471485
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02471485